MYRIAD GENETICS INC — Director's Dealing 2020

Aug 14, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: MYRIAD GENETICS INC (MYGN)
CIK: 0000899923
Period of Report: 2020-08-13

Reporting Person: DIAZ PAUL J (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-08-13	Common Stock	A	298954	$0.00	Acquired	298954	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-08-13	Performance-Based Stock Option	$13.38	A	339088	Acquired	2027-08-13	Common Stock (339088)	Direct
2020-08-13	Time-Based Stock Option	$13.38	A	342040	Acquired	2027-08-13	Common Stock (342040)	Direct

Footnotes

F1: Consists of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests as to 50% of the shares on August 13, 2021, 16.66% of the shares on August 13, 2022, 16.66% of the shares on August 13, 2023, and 16.68% of the shares on August 13, 2024.

F2: The shares subject to the Performance-Based Stock Option become eligible to vest upon achievement of certain stock price targets and will vest as to 20% of the shares upon achievement of each of five stock price targets; provided that no portion of the Performance-Based Stock Option may vest earlier than August 13, 2021.

F3: The shares subject to the Time-Based Stock Option will vest as to 25% of the shares on each of August 13, 2021, August 13, 2022, August 13, 2023 and August 13, 2024.